Why Is Replimune Group (REPL) Stock Down -16.29% Today?
Key Takeaways
- Replimune Group shares plunged 16.29% in Monday's trading session, falling to $8.12 from Friday's close of $9.70.
- A securities registration filing (S-3/A) submitted on July 24 raised immediate dilution concerns among investors, triggering a sharp sell-off in the first session following the disclosure.
- Mounting anxiety ahead of the FDA's Oncologic Drugs Advisory Committee (ODAC) meeting, expected this week, added to the stock's downward pressure as traders de-risk before a binary regulatory event.
- Elevated short interest of more than 30% of float amplified the decline, as bearish positioning and momentum selling fed a cascading effect.
- The stock has now shed roughly 26% in a week, reflecting a broader loss of confidence ahead of the August 2 FDA decision date for RP1.
- Upcoming earnings on August 3 — the day after the FDA decision — add another layer of event risk that traders are actively repricing.
Opening Summary
REPL, the stock of Replimune Group, Inc. — a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer — tumbled 16.29% on Monday, marking one of its steepest single-day declines in months. The shares last traded at $8.12, down sharply from the prior session's close of $9.70, as a convergence of regulatory uncertainty, potential equity dilution, and pre-binary-event positioning rattled investor confidence. The sell-off extends a multiday losing streak that has now erased more than a quarter of the stock's value from its July 21 peak of $11.00.
Registration Statement Filing Sparks Dilution Fears
The proximate catalyst for Monday's plunge traces back to a filing submitted after Friday's close. Replimune lodged an S-3/A registration statement with the Securities and Exchange Commission on July 24, detailing a potential securities offering. For a pre-revenue, clinical-stage biotech company that booked a net loss of $313.94 million in its most recent fiscal year, any indication of a forthcoming capital raise invites immediate concern about shareholder dilution. With no product revenue and a cash runway that management has previously guided into early 2027, the market interpreted the filing as a signal that Replimune may be preparing to tap equity markets — potentially at prices well below where the stock traded just days ago.
ODAC Meeting Looms as Binary Catalyst Approaches
Beyond the registration filing, REPL faces what many traders consider the defining event in the company's history: the FDA's Oncologic Drugs Advisory Committee (ODAC) meeting, expected this week, followed by a final FDA decision on the company's lead therapeutic candidate RP1 by August 2. RP1 — a genetically engineered oncolytic virus designed to treat advanced melanoma in patients who have progressed on anti-PD-1 therapy — has already been rejected twice by the FDA, in July 2025 and April 2026. While the agency accepted a third resubmission in June and granted an expedited review, the track record of two prior Complete Response Letters weighs heavily on sentiment. The prospect of a third rejection — which could effectively terminate the program — is driving risk-averse positioning across the trading community.
Technical Breakdown and Elevated Short Interest
The magnitude of Monday's drop was exacerbated by the stock's heavily shorted status. With short interest exceeding 30% of the public float, REPL remains one of the most shorted names in the mid-cap biotech space. When bearish momentum intensifies, this level of short positioning can amplify downward price swings as stop-loss orders trigger and margin-sensitive longs are forced to reduce exposure. The stock has now broken decisively below its 50-day moving average and is testing levels not seen since early June, before the FDA resubmission announcement sparked a rally. Volume on Monday surged well above the average, reflecting conviction behind the sell-off.
Broader Market and Sector Context
The decline in REPL also unfolded against a backdrop of sector-wide pressure on pre-revenue biotech names, particularly those with concentrated binary catalysts. The broader healthcare sector has experienced selective selling as traders reassess risk exposure heading into a week dense with FDA advisory panels and decision dates. While the S&P 500 and major indices opened the week relatively flat, speculative biotech names with near-term regulatory outcomes faced disproportionate selling, suggesting a rotation out of event-driven risk.
What Comes Next for REPL
The coming days represent a make-or-break period for REPL. The ODAC meeting — whenever it convenes this week — will provide the first public signal of how the expert panel views RP1's risk-benefit profile. A negative panel vote could send shares sharply lower ahead of the August 2 final decision, while a favorable recommendation could trigger a substantial relief rally. Adding to the complexity, Replimune is scheduled to report earnings on August 3, the day after the FDA decision, creating an unusually dense cluster of high-impact events. Analysts remain divided: BMO Capital and JPMorgan have issued bullish calls tied to the FDA pathway, while other firms maintain Hold or Sell ratings, reflecting deep uncertainty. Traders should also monitor the registration statement for any updates on pricing, deal size, or timing, as those details could materially affect the dilution calculus.
Trending AI Robots
In volatile market conditions like those surrounding REPL, traders often turn to automated strategies to help navigate binary events and rapid price swings. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed to identify opportunities across thousands of tickers. These bots vary by strategy, timeframe, performance metrics, and traded symbols, but only the strongest performers under current market conditions are featured. Exploring the Trending AI Robots section can help traders discover data-driven tools calibrated for today's market dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
REPL's Stochastic Oscillator remains in overbought zone for 13 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for REPL moved out of overbought territory on August 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for REPL entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on REPL as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for REPL just turned positive on August 04, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
REPL moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on August 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .
REPL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.175) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.692).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement